Dynavax Prices Public Offering of Common Stock
May 9, 2012
Dynavax Announces Proposed Public Offering of Common Stock
May 8, 2012
Dynavax Embarks on Transition to Commercialization
May 8, 2012
Dynavax Reports First Quarter 2012 Financial Results
April 27, 2012
Dynavax Reports HEPLISAV(TM) BLA Submission
April 26, 2012
Dynavax Reports Final Phase 3 Data for HEPLISAV(TM) in CKD Patients and New Data From Booster Trial in Hemodialysis Patients
March 27, 2012
Phase 3 Data on HEPLISAV(TM) in Adults Aged 40-70 Published in VACCINE
March 13, 2012
Dynavax Reports Fourth Quarter and Year End 2011 Financial Results
March 6, 2012
Phase 3 Data on HEPLISAV(TM) in Adults Aged 18-55 Published in VACCINE
February 13, 2012
Dynavax Reports on Heplisav(TM) Pre-BLA Meeting With FDA
February 2, 2012
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma
December 21, 2011
Dynavax Initiates Proof of Mechanism Trial in Lupus Patients
December 20, 2011
Dynavax Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock
November 8, 2011
Dynavax Prices Public Offering of Common Stock
November 3, 2011
Dynavax Announces Proposed Public Offering of Common Stock
November 2, 2011
Dynavax Confirms HEPLISAV(TM) Submission Strategies With U.S. FDA and EMA
October 27, 2011
Dynavax Reports Third Quarter 2011 Financial Results
October 27, 2011
Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of HEPLISAV(TM) vs Engerix-B(R)
October 27, 2011
Analyst & Investor Day Webcast
October 27, 2011
Data From Two Phase 3 Studies Demonstrate HEPLISAV's Superiority in Immunizing Persons With Diabetes From Hepatitis B
October 25, 2011
Dynavax and GlaxoSmithKline Expand Their Worldwide Strategic Alliance
October 21, 2011
Dynavax to Present at Newsmakers in the Biotech Industry Conference
October 14, 2011
Dynavax to Host Analyst & Investor Day Webcast October 27, 2011
October 12, 2011
More...
|
Our clinical-stage pipeline includes product candidates for the prevention and treatment of infectious diseases. More...
|
Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious diseases.
Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, and Novartis, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.
Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product, HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.
|
